HAEMONETICS CORP

Listed Company

HAECIK 0000313143NYSELarge AcceleratedSurgical & Medical Instruments & ApparatusMassachusettsFY ends Mar 28

Period

FY 2026

Revenue

$1.33B

Net Income

$97.31M

Total Assets

$2.40B

Equity

$796.32M

Shares Out

45.45M

Op. Cash Flow

$293.22M

Business

HAEMONETICS CORP is a global medical technology company that develops and supplies devices, software and services to improve blood and plasma collection, transfusion and perioperative care. It offers automated plasma collection systems, donor management and supply‑chain software, blood collection and processing devices and disposables, vascular closure and sensor‑guided devices, esophageal protection systems, hemostasis analyzers, cell salvage equipment and transfusion management software. The company operates through three reporting segments: Plasma, Blood Center and Hospital (Interventional Technologies and Blood Management Technologies). It sells products in approximately 95 countries through a direct sales force and independent distributors to biopharmaceutical companies, blood centers, hospitals, group purchasing organizations and national health organizations.

Summary from filing dated 2025-05-21

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	Mar 28, 2026 2026-03-28	Mar 29, 2025 2025-03-29	Mar 30, 2024 2024-03-30
Net revenues	1,334	1,361	1,309
Cost of goods sold	546	612	618
Gross profit	788	749	692
Operating expenses:	—	—	—
Research and development	60	63	54
Selling, general and administrative	442	437	430
Amortization of acquired intangible assets	44	48	32
Remeasurement of contingent consideration	−2	−23	0
Impairment of intangible assets	87	2	10
Total operating expenses	631	527	527
Operating income	157	222	165
Interest and other expense, net	−29	−10	−13
Income before provision for income taxes	128	212	152
Provision for income taxes	31	44	34
Net income	97	168	118
Net income per share:	—	—	—
Basic (in dollars per share)	2.06	3.33	2.32
Diluted (in dollars per share)	2.05	3.31	2.29
Weighted average shares outstanding	—	—	—
Basic (in shares)	47	50	51
Diluted (in shares)	47	51	51

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	Mar 28, 2026 2026-03-28	Mar 29, 2025 2025-03-29
ASSETS	—	—
Current assets:	—	—
Cash and cash equivalents	245	307
Accounts receivable, less allowance for credit losses of $3,693 as of March 28, 2026 and $6,300 as of March 29, 2025	217	203
Inventories, net	306	365
Prepaid expenses and other current assets	66	60
Total current assets	835	935
Property, plant and equipment, net	306	284
Intangible assets, less accumulated amortization of $363,763 as of March 28, 2026 and $316,313 as of March 29, 2025	448	456
Goodwill	656	604
Deferred tax asset	10	8
Other long-term assets	142	164
Total assets	2,396	2,451
LIABILITIES AND STOCKHOLDERS’ EQUITY	—	—
Current liabilities:	—	—
Notes payable and current maturities of long-term debt	5	304
Accounts payable	51	67
Accrued payroll and related costs	68	59
Other current liabilities	158	148
Total current liabilities	283	578
Long-term debt, net of current maturities	1,220	921
Deferred tax liability	38	63
Other long-term liabilities	59	68
Stockholders’ equity:	—	—
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 45,252,667 shares as of March 28, 2026 and 48,215,899 shares as of March 29, 2025	453,000	482,000
Additional paid-in capital	554	523
Retained earnings	279	352
Accumulated other comprehensive loss	−38	−55
Total stockholders’ equity	796	821
Total liabilities and stockholders’ equity	2,396	2,451

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	Mar 28, 2026 2026-03-28	Mar 29, 2025 2025-03-29	Mar 30, 2024 2024-03-30
Cash Flows from Operating Activities:	—	—	—
Net income	97	168	118
Adjustments to reconcile net income to net cash provided by operating activities:	—	—	—
Depreciation and amortization	112	116	97
Amortization of fair value inventory step-up	6	15	3
Share-based compensation expense	34	30	28
Impairment of intangible assets	87	2	10
Gain on repurchase of convertible senior notes, net	0	13	0
Gains on sales of property, plant and equipment	714,000	16	1
Remeasurement of contingent consideration	−2	−23	0
Deferred income taxes	−26	−5	−11
Other non-cash operating activities	11	10	12
Change in operating assets and liabilities:	—	—	—
Change in accounts receivable	15	−7	24
Change in inventories	−47	65	60
Change in prepaid income taxes	5	−226,000	983,000
Change in other assets and other liabilities	35	25	34
Change in accounts payable and accrued expenses	−17	−19	45
Net cash provided by operating activities	293	182	182
Cash Flows from Investing Activities:	—	—	—
Capital expenditures	33	39	38
Proceeds from divestiture and sale of assets	0	43	2
Proceeds from sale of property, plant and equipment	1	23	2
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment	−52	−21	−28
Acquisitions	60	151	244
Other investments	36	17	16
Net cash used in investing activities	−180	−162	−322
Cash Flows from Financing Activities:	—	—	—
Proceeds from issuance of convertible notes	0	700	0
Repayment and repurchase of convertible notes	300	186	0
Purchase of capped call related to convertible notes	0	88	0
Term loan borrowings	0	250	0
Term loan redemption	0	263	0
Repayment of term loan borrowings	6	5	12
Proceeds from revolving facility	300	0	110
Payments on revolving facility	0	50	60
Debt issuance costs	0	23	0
Proceeds from employee stock purchase plan	8	8	7
Cash used to net share settle employee equity awards	5	10	6
Share repurchases	175	225	0
Other financing activities	−102,000	−249,000	−922,000
Net cash (used in) provided by financing activities	−178	109	38
Effect of exchange rates on cash and cash equivalents	3	−685,000	−3
Net Change in Cash and Cash Equivalents	−61	128	−106
Cash and Cash Equivalents at End of Year	—	—	—
Cash and Cash Equivalents at End of Year	—	—	—
Supplemental Disclosures of Cash Flow Information:	—	—	—
Interest paid	17	17	21
Income taxes paid	61	49	53
Fair value of previously held equity interest settled in connection with acquisition	47	0	0
Settlement of pre-existing loan in connection with acquisition	36	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro